Literature DB >> 11337497

Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells.

B H Morrison1, J A Bauer, D V Kalvakolanu, D J Lindner.   

Abstract

Interferons (IFNs) regulate the expression of genes that mediate their antiviral, antitumor, and immunomodulatory actions. We have previously shown that IFN-beta suppresses growth of human ovarian carcinoma xenografts in vivo and induces apoptosis of ovarian carcinoma cells in vitro. To investigate mechanisms of IFN-beta-induced apoptosis we employed an antisense technical knockout approach to identify gene products that mediate cell death and have isolated several regulators of interferon-induced death (RIDs). In this investigation, we have characterized one of the RIDs, RID-2. Sequence analysis revealed that RID-2 was identical to human inositol hexakisphosphate kinase 2 (IP6K2). IP6K2 is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells. A mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta-induced apoptosis. These studies identify a novel function for IP6K2 in cell growth regulation and apoptosis.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11337497      PMCID： PMC2025680          DOI： 10.1074/jbc.M101161200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  STATs and gene regulation.

Authors:  J E Darnell
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

Review 2.  The PKR protein kinase--an interferon-inducible regulator of cell growth and differentiation.

Authors:  C E Samuel; K L Kuhen; C X George; L G Ortega; R Rende-Fournier; H Tanaka
Journal:  Int J Hematol       Date:  1997-04       Impact factor: 2.490

3.  Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.

Authors:  D J Lindner; E C Borden
Journal:  J Interferon Cytokine Res       Date:  1997-11       Impact factor: 2.607

4.  Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

Authors:  T Holtschke; J Löhler; Y Kanno; T Fehr; N Giese; F Rosenbauer; J Lou; K P Knobeloch; L Gabriele; J F Waring; M F Bachmann; R M Zinkernagel; H C Morse; K Ozato; I Horak
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  Structural identification of the myo-inositol 1,4,5-trisphosphate-binding domain in rat brain inositol 1,4,5-trisphosphate 3-kinase.

Authors:  S Togashi; K Takazawa; T Endo; C Erneux; T Onaya
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

6.  Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons.

Authors:  T Raveh; A G Hovanessian; E F Meurs; N Sonenberg; A Kimchi
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

7.  p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines.

Authors:  M Rämet; K Castrén; K Järvinen; K Pekkala; T Turpeenniemi-Hujanen; Y Soini; P Pääkkö; K Vähäkangas
Journal:  Carcinogenesis       Date:  1995-09       Impact factor: 4.944

8.  Synthesis and metabolism of bis-diphosphoinositol tetrakisphosphate in vitro and in vivo.

Authors:  S B Shears; N Ali; A Craxton; M E Bembenek
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

9.  Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation.

Authors:  G N Barber; M Wambach; S Thompson; R Jagus; M G Katze
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

10.  Purified inositol hexakisphosphate kinase is an ATP synthase: diphosphoinositol pentakisphosphate as a high-energy phosphate donor.

Authors:  S M Voglmaier; M E Bembenek; A I Kaplin; G Dormán; J D Olszewski; G D Prestwich; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205
View more
  66 in total

Review 1.  How versatile are inositol phosphate kinases?

Authors:  Stephen B Shears
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

2.  Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.

Authors:  Chiara Grisanzio; Lillian Werner; David Takeda; Bisola C Awoyemi; Mark M Pomerantz; Hiroki Yamada; Prasanna Sooriakumaran; Brian D Robinson; Robert Leung; Anna C Schinzel; Ian Mills; Helen Ross-Adams; David E Neal; Masahito Kido; Toshihiro Yamamoto; Gillian Petrozziello; Edward C Stack; Rosina Lis; Philip W Kantoff; Massimo Loda; Oliver Sartor; Shin Egawa; Ashutosh K Tewari; William C Hahn; Matthew L Freedman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-22       Impact factor: 11.205

3.  p53-mediated apoptosis requires inositol hexakisphosphate kinase-2.

Authors:  Michael A Koldobskiy; Anutosh Chakraborty; J Kent Werner; Adele M Snowman; Krishna R Juluri; M Scott Vandiver; Seyun Kim; Shira Heletz; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  Changes in cellular levels of inositol polyphosphates during apoptosis.

Authors:  Rakhee Agarwal; Samar Hassen; Nawab Ali
Journal:  Mol Cell Biochem       Date:  2010-08-20       Impact factor: 3.396

Review 5.  The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Authors:  Mark P Thomas; Stephen J Mills; Barry V L Potter
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-22       Impact factor: 15.336

6.  Inositol hexakisphosphate kinase-2 determines cellular energy dynamics by regulating creatine kinase-B.

Authors:  Latika Nagpal; Michael D Kornberg; Lauren K Albacarys; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

Review 7.  Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate.

Authors:  Karsten Sauer; Michael P Cooke
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

8.  HSP90 regulates cell survival via inositol hexakisphosphate kinase-2.

Authors:  Anutosh Chakraborty; Michael A Koldobskiy; Katherine M Sixt; Krishna R Juluri; Asif K Mustafa; Adele M Snowman; Damian B van Rossum; Randen L Patterson; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

9.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.

Authors:  Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian L Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

10.  IP6K2 is a client for HSP90 and a target for cancer therapeutics development.

Authors:  David S Shames; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.